Loading...
•
Oct 31, 2024
Engene Q4 2024 Earnings Report
enGene reported full year 2024 financial results and provided a business update.
Key Takeaways
enGene reported cash, cash equivalents and marketable securities of $297.9 million, which are expected to fund operations into 2027. The company also announced a BLA filing for detalimogene in BCG-unresponsive NMIBC with CIS on track for mid-2026.
BLA filing for detalimogene in BCG-unresponsive NMIBC with CIS on track for mid-2026.
All cohorts of the Phase 2 LEGEND study are now recruiting under the updated protocol.
Additional preliminary data from the pivotal cohort is anticipated in 2H 2025.
Cash, cash equivalents and marketable securities of $297.9 million provide runway into 2027.
Engene
Engene
Forward Guidance
enGene expects that its existing cash and cash equivalents will fund operating expenses, debt obligations and capital expenditures into 2027.